# High-Dose Isoniazid Among Adult Patients With Different Genetic Variants of INH-Resistant Tuberculosis (TB)

> **NCT01936831** · PHASE2 · COMPLETED · sponsor: **Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections** · enrollment: 282 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** Isoniazid
- **DIETARY_SUPPLEMENT:** Vitamin B6

## Key facts

- **NCT ID:** NCT01936831
- **Lead sponsor:** Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-13
- **Primary completion:** 2021-09-22
- **Final completion:** 2021-10-06
- **Target enrollment:** 282 (ACTUAL)
- **Last updated:** 2023-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01936831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01936831, "High-Dose Isoniazid Among Adult Patients With Different Genetic Variants of INH-Resistant Tuberculosis (TB)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01936831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*